RESUMO
COVID-19 has had a catastrophic effect on healthcare systems compromising the treatment of cancer patients. It has an increased disease burden in the cancer population. As a result, tele-oncology services have become essential to reduce the risk of cancer patients being exposed to the deadly pathogen. Many governmental establishments have endorsed the use of tele-oncology during COVID-19 era. However, telemedicine in oncology still has certain drawbacks that can be improved upon. Nevertheless, tele-oncology has shown great promise to support cancer care not only during this pandemic but also become a part of normal care in the future.
Assuntos
Betacoronavirus , Infecções por Coronavirus/epidemiologia , Atenção à Saúde/métodos , Oncologia , Neoplasias/epidemiologia , Pandemias , Pneumonia Viral/epidemiologia , Telemedicina/métodos , COVID-19 , Terapia Combinada , Comorbidade/tendências , Humanos , Neoplasias/terapia , SARS-CoV-2Assuntos
Infecções por Coronavirus , Oncologia , Neoplasias , Pandemias , Pneumonia Viral , Estudantes de Medicina , Telemedicina , Betacoronavirus , COVID-19 , Humanos , SARS-CoV-2RESUMO
COVID-19 has had a devastating impact on the care of cancer patients. Thus, tele-oncology has become a necessity to improve cancer care. Several organisations have issued guidelines for its use during COVID-19. Despite certain shortcomings, tele-oncology has great potential to help cancer patients during COVID-19 and in the future.
